Skip to main content
Jeffery M. Klco, MD, PhD
Jeffery M. Klco, MD, PhD

Jeffery M. Klco, MD, PhD

Associate Member, St. Jude Faculty

  • Director, Division of Hematopathology and Molecular Pathology

Departments

Education

MD, PhD – Washington University School of Medicine, St. Louis, MO
Resident Physician – Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, MO
Fellow – Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, MO
BS – Boston College, Boston, MA

Honors & Awards

  • 2017 V Foundation, Scholar (Pediatric Cancer Research) Grant Recipient
  • 2015 American Society of Clinical Investigation Young Investigator Award
  • 2014-present Burroughs Wellcome Fund, Career Award for Medical Scientists
  • 2013-present NIH/NHLBI Clinical Scientist Career Development Award (K08)
  • 2013-2015 NIH/NCI Loan Repayment Program recipient

Research interests

  • Genomic and functional characterization of acute myeloid leukemia and myelodysplastic syndromes
  • Using experimental in vivo and in vitro approaches to study signaling pathways in myeloid development
  • Using genomic information to improve the outcome and risk stratification of children with cancer

Selected Publications

Elsayed A, Rafiee R, Cao X, Raimondi S, Downing J, Ribeiro R, Fan Y, Gruber T, Baker S, Klco J, Rubnitz J, Pounds S, Lamba J. A 6-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia 34(3):735-745, 2020.

Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, Klco JM, Helton NM, O’Laughlin M, Fronick CC, Fulton RS, Wilson RK, Wartman LD, Welch JS, Heath SE, Baty JD, Payton JE, Graubert TA, Link DC, Walter MJ, Westervelt P, Ley TJ, DiPersio JF. Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. NEJM 379(24): 2330-2341, 2018. 

Rusch M, Nakitandwe J, Shurtleff S, Newman S, Zhang Z, Edmonson MN, Parker M, Jiao Y, Ma X, Liu Y,  Gu J, Walsh MF, Becksfort J, Thrasher A, Li Y, McMurry J, Hedlund E, Patel A, Easton J, Yergeau D, Vadodaria B, Tatevossian RG, Raimondi S, Hedges D,  Chen X, Hagiwara K, McGee R , Robinson GW, Klco JM, Gruber TA, Ellison DW, Downing JR, Zhang J. Clinical Cancer Genomic Profiling by Three-Platform Sequencing of Whole Genome, Whole Exome and Transcriptome. Nature Communications 9(1):3962, 2018.

Wong JC, Bryant V, Lamprecht T, Ma J, Walsh M, Schwartz J, Alzamora M, Mullighan CG, Loh ML, Ribeiro R, Downing JR, Carroll WL, Davis J, Gold S, Rogers PC, Israels S, Yanofsky R, Shannon K, Klco JM. Germline SAMD9 and SAMD9L Mutations Are Associated with Extensive Genetic Evolution and Diverse Hematologic Outcomes. JCI Insight 3(14):e121086, 2018.

Schwartz JR, Ma J, Lamprecht T, Walsh M, Wang S, Bryant V, Song G, Wu G, Easton J, Kesserwan C, Nichols KE, Mullighan CG, Ribeiro RC, Klco JM. The Genomic Landscape of Pediatric Myelodysplastic Syndromes. Nature Communications 8(1):1557, 2017. PMCID: PMC5691144

Schwartz JR, Wang S, Ma J, Lamprecht T, Walsh M, Song G, Raimondi SC, Wu G, Walsh MF, McGee RB, Kesserwan C, Nichols KE, Cauff BE, Ribeiro RC, Wlodarski M, Klco JM. Germline SAMD9 Mutation in Siblings with Monosomy 7 and Myelodysplastic Syndrome. Leukemia 31(8):1827-1830, 2017. PMID:28487541

Faber ZJ, Chen X, Larson Gedman A, Boggs K, Cheng J, Ma J, Radtke I, Chao J, Walsh MP, Song G, Andersson AK, Dang J, Dong L, Liu Y, Huether R, Cai Z, Mulder H, Wu G, Edmonson M, Rusch M, Qu C, Li Y, Vadodaria B, Wang J, Hedlund E, Cao X, Yergeau D, Nakitandwe J, Pounds SB, Shurtleff S, Fulton RS, Fulton LF, Easton J, Parganas E, Pui C, Rubnitz JE, Ding L, Mardis ER, Wilson RK, Gruber TA, Mullighan CG, Schlenk RF, Paschka P, Döhner C, Döhner H, Bullinger L*, Zhang J*Klco JM*, Downing JR*. *Co-corresponding author. The Genomic Landscape of Core-Binding Factor Acute Myeloid Leukemias. Nature Genetics 48(12):1551-1556, 2016. PMID: 27798625

Griffith M, Griffith OL, Krysiak K, Skidmore ZL, Christopher MJ, Klco JM, Ramu A, Lamprecht TL, Wagner AH, Campbell KM, Lesurf R, Hundal J, Zhang J, Spies NC, Ainscough BJ, Larson DE, Heath SE, Fronick C, O'Laughlin S, Fulton R, Magrini V, McGrath S, Smith SM, Miller CA, Maher CA, Payton JE, Walker JR, Eldred JM, Walter MJ, Link DC, Graubert TA, Westervelt P, Kulkarni S, DiPersio JF, Mardis ER, Wilson RK, Ley TJ. Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B lymphoblastic leukemia. Exp Hematol 44(7):603-613, 2016.

Wong TN, Miller CA, Klco JM, Petti A, Demeter R, Helton NM, Li T, Fulton RS, Heath SE, Mardis ER, Westervelt P, DiPersio JF, Walter MJ, Welch JS, Graubert TA, Wilson RK, Ley TJ, Link DC. Rapid expansion of pre-existing non-leukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood Feb 18;127(7):893-7, 2015.

Griffith M*, Miller CA*, Griffith OL, Krysiak K, Skidmore ZL, Ramu A, Walker JR, Dang HX, Trani L, Larson DE , Demeter RT, Wendl MC, McMichael JF, Austin R, Magrini VJ, McGrath SD, Ly A, Kulkarni S, Cordes M, Fronick CC, Fulton RS, Maher CA, Ding L, Klco JM, Mardis ER, Ley TJ, Wilson RK. Optimizing cancer genome sequencing and analysis. *Authors contributed equally. Cell Systems 1(3):210-223, 2015.

 Klco JM*, Miller CA*, Griffith M, Petti A,  Spencer DH, Ketkar-Kulkarni S,  Wartman LD, Christopher M, Lamprecht TL, Helton NM, Duncavage EJ, Payton JE, Baty J, Heath SE, Griffith OL,  Shen D, Hundal J, Chang GS, Fulton R, O'Laughlin M, Fronick C, Magrini V, Demeter RT, Larson DE, Kulkarni S, Ozenberger BA, Welch JS, Walter MJ, Graubert TA, Westervelt P, Radich JP, Link DC, Mardis ER, DiPersio JF, Wilson RK, Ley TJ. Correlating genomic assessment of mutation clearance after induction therapy and outcomes among adult patients with acute myeloid leukemia. *Authors contributed equally. JAMA 314(8):811-822, 2015.

Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, Lamprecht TL, Shen D, Hundal J, Fulton RS, Heath S, Baty JD, Klco JM, Ding L, Mardis ER, Westervelt P, DiPersio JF, Walter MJ, Graubert TA, Ley TJ, Druley TE, Link DC, Wilson RK. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518(7540):552-5, 2014.

Sarkaria SM, Christopher MJ, Klco JM, Ley TJ. Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro. Leukemia 28(12):2403-6, 2014. 

Klco JM*, Spencer DH*, Miller CA, Griffith M, Lamprecht TL, O’Laughlin M,  Fronick C, Magrini V, Demeter RT, Fulton RS, Eades WC, Link DC, Graubert TA, Walter MJ, Mardis ER, Dipersio JF, Wilson RK, Ley TJ. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. *Authors contributed equally. Cancer Cell 25(3):379-92, 2014.

Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. NEJM May 30;368(22):2059-74, 2013.

Klco JM*, Spencer DH*, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V, Hundal J, Walker J, Varghese N, Erdmann-Gilmore P, Lichti CF, Meyer MR, Townsend RR, Wilson RK, Mardis ER, Ley TJ. Genomic impact of transient low-dose decitabine treatment on primary AML cells. * Authors contributed equally. Blood 121(9):1633-43, 2013.

Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, Wartman LD, Lamprecht TL, Liu F, Xia J, Kandoth C, Fulton RS, McLellan MD, Dooling DJ, Wallis JW, Chen K, Harris CC, Schmidt HK, Kalicki-Veizer JM, Lu C, Zhang Q, Lin L, O'Laughlin MD, McMichael JF, Delehaunty KD, Fulton LA, Magrini VJ, McGrath SD, Demeter RT, Vickery TL, Hundal J, Cook LL, Swift GW, Reed JP, Alldredge PA, Wylie TN, Walker JR, Watson MA, Heath SE, Shannon WD, Varghese N, Nagarajan R, Payton JE, Baty JD, Kulkarni S, Klco JM, Tomasson MH, Westervelt P, Walter MJ, Graubert TA, Dipersio JF, Ding L, Mardis ER, Wilson RK. The origin and evolution of mutations in acute myeloid leukemia. Cell (150):264-278, 2012.

Welch JS, Westervelt P, Ding L, Larson DE, Klco JM, Kulkarni S, Wallis J, Chen K, Payton JE, Fulton RS, Veizer J, Schmidt H, Vickery TL, Heath S, Watson MA, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Ley TJ, Wilson RK. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 305(15):1577-84, 2011.

Last update: June 2020

Close